New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
10:04 EDTBEAV, CIT, ISIS, DOC, AWI, MTH, CBB, COL, CTRXOn the Fly: Analyst Initiation Summary
ANI Pharmaceuticals (ANIP) initiated with an Outperform at Oppenheimer... BE Aerospace (BEAV) initiated with a Buy at Topeka... CIT Group (CIT) initiated with a Neutral at Goldman... Fidelity & Guaranty Life (FGL) initiated with a Neutral at JPMorgan... Isis Pharmaceuticals (ISIS) initiated with a Buy at Deutsche Bank... Physicians Realty Trust (DOC) initiated with a Hold at KeyBanc... SLM Corp. (SLM) initiated with a Buy at Goldman... Triumph Group (TGI) initiated with a Hold at Topeka... Valero Energy Partners (VLP) initiated with a Neutral at Citigroup... Xylem (XYL) initiated with an Outperform at Oppenheimer... Armstrong World (AWI) initiated with a Hold at Gabelli... Meritage Homes (MTH) initiated with a Neutral at BofA/Merrill... Exelis (XLS) initiated with an Outperform at Cowen... Cincinnati Bell (CBB) initiated with an Overweight at Stephens... Rockwell Collins (COL) resumed with an Overweight at JPMorgan... Fidelity & Guaranty Life (FGL) initiated with an Outperform at Credit Suisse... Catamaran (CTRX) initiated with a Buy at Argus.
News For BEAV;CIT;ISIS;DOC;AWI;MTH;CBB;COL;CTRX From The Last 14 Days
Check below for free stories on BEAV;CIT;ISIS;DOC;AWI;MTH;CBB;COL;CTRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
19:28 EDTISISIsis Pharmaceutical licensing partner Antisense reports ATL1103 phase II results
Antisense Therapeutics, or ANP, reported the primary efficacy results from its phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I, or sIGF-1, levels of 26% from baseline at week 14 at the 400mg per week dose tested. All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg bodyweight with the patients who received 5.5 mg/kg per week showing a 36% average reduction in their sIGF-I levels. The positive results achieved in this Phase II trial position ATL1103 to move into Phase III stage of development. Consequently, ANP will accelerate out-licencing activities to secure a pharmaceutical development partner for the drug's further development. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals, including ATL1103.
August 29, 2014
16:21 EDTBEAVBE Aerospace files registration statement for spin-off of consumables segment
B/E Aerospace announced a further step in its previously announced separation of its Consumables Management Segment, consisting of the company’s aerospace distribution and energy services businesses, through a distribution, or spin-off, to the company’s shareholders. The company’s subsidiary KLX, to which the separated businesses will be transferred prior to the distribution, filed today a registration statement on Form 10 with the SEC. The spin-off would take the form of a pro rata distribution of all shares of common stock of KLX to B/E shareholders. The company expects the receipt of shares of KLX common stock by B/E shareholders to be tax-free for U.S. federal income tax purposes, except for cash received in lieu of fractional shares. The spin-off is subject to the approval of the Board of Directors of B/E and the satisfaction of certain other conditions. B/E may, at any time until the spin-off, decide to abandon the spin-off or modify or change the terms of the spin-off. Holders of B/E common stock as of the record date for the spin-off will not be required to make any payment, surrender or exchange any shares of B/E common stock or take any other action to participate in the spin-off. Additional information concerning KLX and the proposed spin-off is contained in the registration statement on Form 10.
August 28, 2014
07:05 EDTISISIsis Pharmaceuticals initiates ISIS-APOCIII Phase 3 study
Subscribe for More Information
August 27, 2014
08:30 EDTBEAVMorgan Stanley believes aerospace cycle concerns are overblown
Subscribe for More Information
August 26, 2014
16:32 EDTAWIStarwood appoints Thomas Mangas as CFO
Subscribe for More Information
August 25, 2014
07:59 EDTCTRXSome healthcare providers offer compelling opportunities, says Jefferies
Jefferies believes that the following healthcare providers reported good Q2 results which have not been adequately reflected by their stocks: Acadia Healthcare (ACHC), Almost Family (AFAM), Brookdale Senior Living (BKD), Catamaran (CTRX), Community Health (CYH), Envision Healthcare (EVHC), and HCA Holdings (HCA). The firm expects the sector as a whole to continue to improve in 2H14 amid continued tailwinds from healthcare reform.
August 22, 2014
12:39 EDTISISThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use